CAPR – capricor therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Is It Too Late To Reassess Capricor Therapeutics (CAPR) After Its Recent 130% Surge? [Yahoo! Finance]
Capricor: Moving To 'Buy' Rating As New PDUFA Date Is Set For Deramiocel [Seeking Alpha]
Capricor Therapeutics (CAPR) had its price target raised by B. Riley Financial, Inc. from $50.00 to $63.00. They now have a "buy" rating on the stock.
Capricor Therapeutics (CAPR) had its "overweight" rating reaffirmed by Piper Sandler. They now have a $58.00 price target on the stock, up from $45.00.
Exosome Research Market Analysis, Opportunity Forecasts Report 2026-2035 [Yahoo! Finance]
Form ARS CAPRICOR THERAPEUTICS, For: Dec 31
Form DEF 14A CAPRICOR THERAPEUTICS, For: Jun 04
Form 4 CAPRICOR THERAPEUTICS, For: Apr 02 Filed by: Sabar Karimah Es
Form 144 CAPRICOR THERAPEUTICS, Filed by: Sabar Karimah Es
Form 4 CAPRICOR THERAPEUTICS, For: Mar 31 Filed by: Krasney Karen
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.